secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viridian Therapeutics, Inc.\DE (VRDN)
CIK:        0001590750
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001193125-23-004046
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viridian reports positive Phase 1/2 data for VRDN-001 in thyroid eye disease; 71% proptosis responders across doses
--------------------------------------------------------------------------------

- 3 mg/kg cohort: 67% proptosis responders, 56% overall responders, 67% achieved CAS 0/1, 20% complete diplopia resolution at week 6.
- Across all 21 drug-treated patients: 71% proptosis responders, 67% overall responders, 62% CAS 0/1, 54% complete diplopia resolution.
- No serious adverse events, discontinuations, or infusion reactions reported with VRDN-001 across dose levels.
- Low-dose data support once-monthly subcutaneous dosing profile for VRDN-002 and VRDN-003; VRDN-003 IND planned Q2 2023.
- Phase 3 THRIVE trial enrollment ongoing; results expected mid-2024; chronic TED proof-of-concept data expected H1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590750/000119312523004046/0001193125-23-004046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590750/000119312523004046/d427009d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-004046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer